Protection of patients with diabetes, with or without hypertension: Implications of ADVANCE for clinical practice

Journal of Hypertension

Volumn 27, Issue SUPPL. 1, 2009, Pages

  Mancia, Giuseppe ^a   Grassi, Guido ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Cardiovascular protection; Combination therapy; Hypertension; Indapamide; Perindopril; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO; INDAPAMIDE; PERINDOPRIL;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOTENSION; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT; ARTICLE; BLOOD PRESSURE; PATHOPHYSIOLOGY;

BLOOD PRESSURE; DIABETES MELLITUS; HUMANS; HYPERTENSION; INDAPAMIDE; PERINDOPRIL;

EID: 68049148447     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000354420.23557.e2     Document Type: Review

References (34)

1. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294:466-472.
2. DECODE Study Group. Age-and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26:61-69.
3. Tranche S, Galgo A, Mundet X, Sánchez-Zamorano MA, Karen AP. Cardiovascular risk factors in type 2 diabetic patients: multifactorial intervention in primary care. Kidney Int Suppl 2005; 93:S55-S62. (Pubitemid 40019218)
4. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31:68-72.
5. Julius S, Jamerseon K. Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. J Hypertens 1994; 12:495-502.
6. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002; 51 (Suppl. 1):S117-S121.
7. Hall JE, Brands MW, Hildebrandt DA, Mizelle HL. Obesity-associated hypertension. Hyperinsulinemia and renal mechanisms. Hypertension 1992; 19 (Suppl. 1):I45-I55.
8. Mancia G, Facchetti R, Bombelli M, Polo Friz H, Grassi G, Giannattasio C, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45:1072-1077.
9. Multiple Risk Factor Intervention Trial Research Group. Risk factor changes and mortality results. JAMA 1982; 248:1465-1477.
10. Stratton IM, Cull CA, Adker AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49:1761-1769.
11. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
12. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88-136.
13. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
15. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878. (Pubitemid 34940826)
16. Brenner BN, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869. (Pubitemid 34940825)
17. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal eventsin type 2 diabetes. J Am Soc Nephrol 2009; 20:883-892.
18. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilhope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41:1063-1071.
19. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension. J Nephrol 1997; 10:216-219.
20. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
21. Dahlöf B, Gosse P, Gueret P, Dubourg O, de Simine G, Schmieder R, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23:2063-2070.
22. de LucaN,Mallion JM, O'Rourke MF, O'BrienE,Rahn KH, Trimarco B, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17:660-667.
23. Neglia D, Fommei E,Ghione S, Lombardi M, Donato L, Camici P, et al. Coronary microvascular dysfunction in hypertensive patients with left ventricular hypertrophy can be reversed by treatment with fixed combination of perindopril and indapamide. Eur Heart J 2008; 29 (Abstract Suppl. 1):103.
24. Mourad JJ, Hanon O, Deverre JR, Camici PG, Sellier P, Duboc D, et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldoster Syst 2003; 4:94-95.
25. Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. Diabetologia 1997; 40:476-481.
26. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372:1385-1393.
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
28. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trial. J Hypertens 2002; 20:1461-1464.
29. Kuo SW, Pei D, Hung YJ, Hsieh AT, Wu LY, Hsieh CH, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16:623-628.
30. Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M, ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23:1575-1581.
31. Patel A, MacMahon S, Chalmers J, Neal B,Billot L, Woodward M,et al., and the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
32. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al., and the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
33. Ryden L, Waeber B, Ruilope LM, Mancia G, Volpe M, Holzgreve H, et al. The management of the type 2 diabetic patient with hypertension-too late and too little: suggested improvements. Blood Press 2008; 17:250-259.
34. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.